Evidence map›Paper›PMID 30532012›Full record

ReviewNature reviews. Cancer2019

The lung microenvironment: an important regulator of tumour growth and metastasis.

Nasser K Altorki, Geoffrey J Markowitz, Dingcheng Gao, Jeffrey L Port, Ashish Saxena, Brendon Stiles, Timothy McGraw, Vivek Mittal

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 725 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
725citing papers in PubMed, 2 pooled it
77.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

725 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,167 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Exercise inhibits proliferation and induces apoptosis of lung adenocarcinoma cells via the POU2F2-SPOCD1-PI3K/AKT signaling axis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  11. Article
  12. Article
  13. Single-cell and bulk transcriptomic profiling of metabolism-related lncRNAs reveals tumor heterogeneity and prognostic markers in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. CD49aScientific reports · 2026
    Article

665 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nasser K AltorkiDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Geoffrey J MarkowitzDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Dingcheng GaoDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Jeffrey L PortDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Ashish SaxenaMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Brendon StilesDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Timothy McGrawDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Vivek MittalDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA. vim2010@med.cornell.edu.
Cornell University · USWeill Cornell Medicine · US

Funding

Modeling tumor-stroma crosstalk in lung cancer to identify targets for therapyU01CA188388 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MITTAL, VIVEK, WONG, STEPHEN TC · 2015 to 2019
$2.5M
Molecular and Translational Oncology ResearchT32CA203702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN, GIANNAKAKOU, PARASKEVI · 2017 to 2021
$1.4M
NCI NIH HHS T32 CA203702NCI NIH HHS U01 CA188388
6 · The paper itself

Abstract

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Major advances in the identification of key mutational alterations have led to the development of molecularly targeted therapies, whose efficacy has been limited by emergence of resistance mechanisms. US Food and Drug Administration (FDA)-approved therapies targeting angiogenesis and more recently immune checkpoints have reinvigorated enthusiasm in elucidating the prognostic and pathophysiological roles of the tumour microenvironment in lung cancer. In this Review, we highlight recent advances and emerging concepts for how the tumour-reprogrammed lung microenvironment promotes both primary lung tumours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis, immune modulation and response to therapies. We also discuss the potential of understanding tumour microenvironmental processes to identify biomarkers of clinical utility and to develop novel targeted therapies against lung cancer.

Indexed as

AnimalsBiomarkers, TumorCell ProliferationDrug Resistance, NeoplasmHumansLung NeoplasmsNeoplasm MetastasisNeoplastic ProcessesNeovascularization, PathologicPrognosisTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID30532012
PMCPMC6749995
OpenAlexW2904211489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.